(VIANEWS) – WALLENIUS WILHELMS (WAWI.OL), ASM INTERNATIONAL (ASM.AS), SANOFI (SAN.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. WALLENIUS WILHELMS (WAWI.OL)
1027.3% sales growth and 30.36% return on equity
Wallenius Wilhelmsen ASA, together with its subsidiaries, engages in the logistics and transportation business worldwide. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centers and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes, 66 processing centers, and 8 marine terminals. Wallenius Wilhelmsen ASA was founded in 1861 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr22.37.
PE Ratio
WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 5.7. Meaning, the purchaser of the share is investing kr5.7 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.36%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 25, 2024, the estimated forward annual dividend rate is 18.86 and the estimated forward annual dividend yield is 13.66%.
Volume
Today’s last reported volume for WALLENIUS WILHELMS is 129430 which is 75.9% below its average volume of 537098.
Sales Growth
WALLENIUS WILHELMS’s sales growth is 1029.9% for the present quarter and 1027.3% for the next.
More news about WALLENIUS WILHELMS.
2. ASM INTERNATIONAL (ASM.AS)
26.5% sales growth and 17.12% return on equity
ASM International NV, together with its subsidiaries, engages in the research, development, manufacture, marketing, and servicing of equipment and materials used to produce semiconductor devices in Europe, the United States, and Asia. The company's products include wafer processing deposition systems for atomic layer deposition (ALD), epitaxy, silicon carbide, plasma enhanced chemical vapor deposition (PECVD), and vertical furnace systems, including low pressure chemical vapor deposition (LPCVD), diffusion, and oxidation products, as well as provides spare parts and support services. It also manufactures and sells equipment, which is used in wafer processing, encompassing the fabrication steps in which silicon wafers are layered with semiconductor devices. The company offers its products to semiconductor manufacturers. The company was formerly known as Advanced Semiconductor Materials International NV. ASM International NV was incorporated in 1968 and is headquartered in Almere, the Netherlands.
Earnings Per Share
As for profitability, ASM INTERNATIONAL has a trailing twelve months EPS of €11.17.
PE Ratio
ASM INTERNATIONAL has a trailing twelve months price to earnings ratio of 46.3. Meaning, the purchaser of the share is investing €46.3 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.12%.
More news about ASM INTERNATIONAL.
3. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Volume
Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €90.96 at 07:20 EST, way under its 52-week high of €106.14 and way higher than its 52-week low of €80.60.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
Moving Average
SANOFI’s worth is way under its 50-day moving average of €101.07 and under its 200-day moving average of €92.98.
More news about SANOFI.
4. DASSAULT SYSTEMES (DSY.PA)
6.9% sales growth and 14.34% return on equity
Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS provides easy-to-use 2D and 3D product development solutions accessible to any business; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for intersection of natural resources, infrastructure, and urban planning; and BIOVIA that develops chemicals, biologics, and materials experiences. The company provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. The company distributes its products through direct and indirect sales channels. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; infrastructure, energy, and materials; home and lifestyle; architecture, engineering, and construction; cities, and public services; consumer packaged goods and retail; marine and offshore; and business services. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, DASSAULT SYSTEMES has a trailing twelve months EPS of €0.79.
PE Ratio
DASSAULT SYSTEMES has a trailing twelve months price to earnings ratio of 51.95. Meaning, the purchaser of the share is investing €51.95 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.34%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 27, 2024, the estimated forward annual dividend rate is 0.23 and the estimated forward annual dividend yield is 0.68%.
Yearly Top and Bottom Value
DASSAULT SYSTEMES’s stock is valued at €41.04 at 07:20 EST, way below its 52-week high of €48.88 and way higher than its 52-week low of €32.25.
More news about DASSAULT SYSTEMES.
5. VERALLIA (VRLA.PA)
6% sales growth and 29.81% return on equity
Verallia Société Anonyme manufactures and sells glass packaging products for beverages and food products worldwide. It provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. The company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. Verallia Société Anonyme was founded in 1827 and is based in Courbevoie, France.
Earnings Per Share
As for profitability, VERALLIA has a trailing twelve months EPS of €4.01.
PE Ratio
VERALLIA has a trailing twelve months price to earnings ratio of 8.99. Meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.81%.
More news about VERALLIA.
